CUB domain containing protein 1 (CDPC1) is a target for radioligand therapy in castration resistant prostate cancer
N. Zhao, k. Trepka, Y.-h. Wang, S. Chopra, N. Hooshdaran, H. Kim, J. Yang, J. Zhuo, S. Lim, K. K. Leung, E. Egusa, L. K. Zhang, A. Foye, J. Chou, F. Y. Feng, , R. Aggarwal
This paper evaluates CDCP1 as a target for radioligand therapy in mCRPC, showing its expression in most biopsies and demonstrating antitumor effects with 177Lu-4A06.
bioRxiv · Jun 17, 2021 · PreprintCancer Biology